HK Stock Market Move | INNOCARE (09969) rises more than 3%, expected to submit soon the new drug application for lorlatinib for the treatment of pediatric patients.

INNOCARE (09969) rose by over 3%, up 3.24% as of the time of writing, trading at HK$14 with a turnover of HK$51.05 million. On the news front, on December 11th, Neucell Health announced that the National Medical Products Administration (NMPA) has approved the second-generation small molecule pan-Trk inhibitor (pan-TRK inhibitor) Zotiraciclib (ICP-723) for the treatment of adult and adolescent solid tumor patients carrying NTRK fusion genes aged 12 and above. Zotiraciclib has been included in the "Starlight Plan" by the NMPA, which is a pilot program aimed at encouraging the development of anti-tumor drugs for children. The company expects to soon submit a new drug application (NDA) for Zotiraciclib for the treatment of pediatric patients aged 2 to 12. NTRK fusion genes are present in various types of tumors, and NTRK fusion genes have been found in over 26 solid tumors. It is estimated that there are about 6,500 new cases of NTRK fusion gene-carrying tumors in China each year. These patients typically have a short survival period, rapid disease progression, and a high disability rate. Due to the low popularity of the current gold standard testing method - next-generation sequencing (NGS), leading to delays in diagnosis, there are still unmet clinical needs.